A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics

1. The study evaluated the efficacy of amisulpride, fluoxetine and clomipramine at the beginning of the re-feeding phase of the treatment of restricting anorexia nervosa according to DSM-IV criteria. 2. 13 patients, mean weight 37.61 kg ± 9.80 SD, were treated with clomipramine at a mean dosage of 57.69 mg ± 25.79 SD; 10 patients, mean weight 40.90 kg ± 6.98 SD, were treated with fluoxetine at a mean dosage of 28.00 mg ± 10.32 SD; 12 patients, mean weight 38.41 kg ± 8.33 SD, were treated with amisulpride at a mean dosage of 50.00 mg ± 0.00 SD. 3. Clinical evaluation was carried out under single-blind condition at basal time and after three months by a structured clinical interview, the Eating Disorder Interview based on Long Interval Follow-up Evaluation (LIFE II BEI). 4. Patients treated with amisulpride showed a more significant increase (p=0.016) of mean weight. Concerning weight phobia, body image disturbance and amenorrhoea, no significant difference resulted.